Alto Neuroscience Inc

ANRO remains in a sustained Stage 2 uptrend with price testing rising 9- and 20-day EMA support after a minor pullback from 52-week highs. With EMAs aligned and momentum intact, shallow pullbacks into this zone offer attractive entries while timing remains favorable now.

• ↑Stock gained 9.2% over past two weeks, signaling strong momentum factors.
• ↑“Moderate Buy” consensus with $36.63 target implies 25.8% upside.
• ↓EPS expected to fall from ($3.14) to ($3.56), indicating financial strain.